Icahn School of Medicine, Champions Oncology Evaluating Breast Cancer PGx Technology | GenomeWeb

NEW YORK (GenomeWeb) – The Icahn School of Medicine at Mt. Sinai and Champions Oncology today announced the start of a clinical trial to evaluate the use of the firm's Champions TumorGrafts technology in 100 patients with triple-negative breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.